- Home
- JSPR vs MIST Comparison
JSPR vs MIST Comparison
Compare JSPR & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- MIST
- Stock Information
- Founded
- JSPR 2018
- MIST 2003
- Country
- JSPR United States
- MIST Canada
- Employees
- JSPR N/A
- MIST N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- MIST Health Care
- Exchange
- JSPR Nasdaq
- MIST Nasdaq
- Market Cap
- JSPR 85.8M
- MIST 89.8M
- IPO Year
- JSPR N/A
- MIST N/A
- Fundamental
- Price
- JSPR $5.82
- MIST $1.89
- Analyst Decision
- JSPR Strong Buy
- MIST Strong Buy
- Analyst Count
- JSPR 10
- MIST 2
- Target Price
- JSPR $62.22
- MIST $7.50
- AVG Volume (30 Days)
- JSPR 367.9K
- MIST 595.3K
- Earning Date
- JSPR 08-12-2025
- MIST 08-07-2025
- Dividend Yield
- JSPR N/A
- MIST N/A
- EPS Growth
- JSPR N/A
- MIST N/A
- EPS
- JSPR N/A
- MIST N/A
- Revenue
- JSPR N/A
- MIST N/A
- Revenue This Year
- JSPR N/A
- MIST N/A
- Revenue Next Year
- JSPR N/A
- MIST N/A
- P/E Ratio
- JSPR N/A
- MIST N/A
- Revenue Growth
- JSPR N/A
- MIST N/A
- 52 Week Low
- JSPR $3.13
- MIST $0.63
- 52 Week High
- JSPR $26.05
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- JSPR 53.78
- MIST 67.15
- Support Level
- JSPR $5.35
- MIST $1.85
- Resistance Level
- JSPR $5.91
- MIST $2.02
- Average True Range (ATR)
- JSPR 0.43
- MIST 0.09
- MACD
- JSPR -0.02
- MIST 0.01
- Stochastic Oscillator
- JSPR 64.41
- MIST 77.50
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).